Thalidomide-4-O-CH2-COO (t-Bu)

Thalidomide-4-O-CH2-COO (t-Bu) is t-Bu modified Thalidomide (HY-14658), which is the final step intermediate in the synthesis of Thalidomide-4-OH (HY-123096) . Thalidomide-4-O-CH2-COO (t-Bu) acts as a Cereblon ligand to recruit CRBN proteins. The t-Bu protecting group at the end of Thalidomide-4-O-CH2-COO (t-Bu) can be removed under acidic conditions to participate in the synthesis of PROTAC molecules. Thalidomide-4-O-CH2-COO (t-Bu) is a key intermediate in the synthesis of CRBN-based designed PROTAC molecules.

Product Specifications

CAS Number

[1950635-36-5]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis; Autophagy; E3 Ligase Ligand-Linker Conjugates

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/thalidomide-4-o-ch2-coo-t-bu.html

Purity

99.26

Solubility

10 mM in DMSO

Smiles

O=C1N(C2C(NC(CC2)=O)=O)C(C3=C1C(OCC(OC(C)(C)C)=O)=CC=C3)=O

Molecular Formula

C19H20N2O7

Molecular Weight

388.37

Precautions

H315, H319

References & Citations

[1]Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512 (7512) :49-53. [Content Brief]